Hovione Technology Acquires Rights to New Blister-Based Inhaler

Article

Hovione Technology has acquired global rights to a dry powder inhaler for pulmonary drug delivery, the Papillon DPI invented by Dr. Klaus-Dieter Beller.

Hovione Technology, a HovioneVentures company, announced in an April 15, 2019 press release that it has secured global rights to develop and commercialize a new, affordable, multi-use blister-based dry powder inhaler (DPI) patented by inventor Dr. Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.

The new device is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments. It can accommodate a single- or double-blister configuration. The unit dose costs are competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices, according to the press release.

Hovione Technology has a co-promotional agreement with API manufacturer Hovione, and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development, and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.

Source: Hovione Technology

Recent Videos
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content